Keyword: Moderna Therapeutics
Jamie Macdonald succeeds Joseph von Rickenbach as Parexel CEO, Roche promotes William Pao to replace John Reed as pRED head, Moderna loses vaccines head.
The huge series G round equips Moderna to gather more data on its pipeline of mRNA candidates ahead of its long-anticipated IPO.
Biogen executive Kress jumped to Syntimmune, Mendlein will guide Moderna's strategy and former FDA CIO Perakslis joined Roivant's Datavant.
The round positions BioNTech to mount a multifront attack on cancer, spearheaded by mRNA therapies and supported by modalities including CAR-T cells.
Venture capital firm Flagship Pioneering has got a major $618 million in capital, the biggest in its 17-year history, topping its total to $2.3 billion.
The candidate is designed to induce production of relaxin, a hormone seen as a way to regulate the conditions that exacerbate heart failure.
Gilead boosted oncology chief Riva to EVP, Moderna lost three top R&D officials, Bayer poached Pfizer's consumer marketing vet and more.
A back-loaded deal with CureVac moves Lilly into an emerging field that seeks to use mRNA to guide immune attacks on tumors.
Moderna looks to take an AstraZeneca-partnered med into phase 2 and start on I-O, while making changes to its venture model.
The Big Pharma is paying €25 million to work with Ethris on respiratory diseases and bag the option to license the fruits of the collaboration.